查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1986870

降血脂藥物市場規模、佔有率、趨勢和預測：按藥物類別、給藥途徑、分銷管道和地區分類，2026-2034 年

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2025年全球抗高血脂症藥物市場規模為136億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以3.78%的複合年成長率成長，到2034年達到192億美元。目前，北美市場是主要驅動力，預計2025年將佔據超過32.7%的市場。北美市場成長的主要促進因素包括高血脂症和心血管疾病的高發生率、人口老化、肥胖、久坐的生活方式以及不健康的飲食習慣。此外，強大的研發投入、先進的醫療基礎設施、政府舉措、他汀類藥物、PCSK9抑制劑和新型降脂藥物的日益普及以及醫保覆蓋範圍的擴大，都進一步推動了降血脂藥物市場佔有率的成長。

推動該市場成長的因素包括高血脂症和心血管疾病的日益流行，這兩種疾病仍然是全球主要的死亡原因。老化、肥胖和久坐的生活方式會導致膽固醇水平升高，從而推高了對降血脂藥物的需求。他汀類藥物、貝特類藥物、膽汁酸結合劑和PCSK9抑制劑的廣泛應用，以及貝培多酸等新型治療方法的出現，正在拓展治療選擇。政府所推行的膽固醇管理、預防保健和醫療保險報銷政策等舉措，進一步促進了市場成長。藥物傳遞技術的新方法，透過將治療方法與個人化醫療策略相結合，正在改善治療效果。不斷提高的健康意識，加上保險覆蓋範圍的擴大和製藥公司持續的研發投入，正在推動創新解決方案的湧現，這些解決方案正在發達市場和新興市場蓬勃發展。

美國抗高血脂症藥物市場仍然受到高血脂症、肥胖和心血管疾病高發生率的驅動，這些疾病仍然是發病率和死亡率的主要原因。根據《美國預防醫學雜誌》（AJPM）報告，高血脂症在美國人群中十分常見。在美國，約有32.8%的成年男性和36.2%的成年女性的總膽固醇水平達到或超過200 mg/dL，或低密度脂蛋白膽固醇（LDL-C）水平達到或超過130 mg/dL。老化、缺乏運動和不良飲食習慣會導致膽固醇水平升高，從而增加對降血脂藥物的需求。他汀類藥物、PCSK9抑制劑和新型降脂療法的廣泛應用得益於完善的醫療保健基礎設施、保險覆蓋範圍以及政府促進心血管健康的措施。美國食品藥物管理局 (FDA)核准新的降血脂藥物，持續增加對藥物研發的投資，以及個人化醫療和生物製藥療法的推廣，進一步加速了該國市場的成長。

降血脂藥物市場趨勢：

高血脂症和心血管疾病盛行率增加

高血脂症、肥胖和心血管疾病 (CVD) 發病率的上升是抗高血脂症藥物市場的主要促進因素。例如，非傳染性疾病風險因子協作組織 (NCD-RisC) 發布的數據顯示，到 2024 年，全球將有超過 10 億人肥胖，其中包括約 8.8 億成年人和 1.59 億 5 至 19 歲的兒童和青少年。世界肥胖聯盟分析的數據顯示，約有 30 億人超重或肥胖，而且地球上絕大多數人居住在超重或肥胖比體重過輕更容易造成健康風險的國家。不健康的飲食習慣、久坐的生活方式和遺傳傾向會導致高膽固醇水平，從而推動了對降血脂藥物的需求。心肌梗塞、中風和動脈粥狀硬化是全球主要的死亡原因，迫使醫療專業人員開立他汀類藥物、PCSK9 抑制劑和其他降血脂療法。各國政府和醫療機構都在積極推廣膽固醇管理項目，這進一步推動了市場成長。由於心血管疾病仍然是主要的公共衛生問題，因此對有效的長期膽固醇管理方案的需求持續上升。

降血脂療法的進展與藥物創新

降血脂藥物的持續研發催生了多種新型藥物，包括PCSK9抑制劑（依洛尤單抗、阿利西尤單抗）、貝培多酸以及聯合治療。儘管他汀類藥物仍佔據市場主導地位，但這些新治療方法為對他汀類藥物不耐受或血脂異常高風險的患者提供了新的治療選擇。基因療法和生物製藥也日益受到關注，它們在提高療效和患者依從性方面發揮重要作用。 FDA對新藥的核准以及探索下一代降脂藥物的臨床試驗進一步加劇了市場競爭。製藥公司正增加對精準醫療、人工智慧驅動的藥物研發以及聯合製劑的投資，以強化其膽固醇管理方案。例如，2025年2月，FDA核准了Ctexli（kenodiolus）用於治療成人腦腱黃斑部病變（CTX）。 Ctexli是FDA核准的首個用於治療CTX的藥物，CTX是一種罕見的脂質貯積症候群。

政府主導的措施和醫療保險的擴大

政府主導的醫療保健計劃和宣傳宣傳活動正在推動對降血脂藥物的需求。許多國家正在製定膽固醇檢測指南、報銷政策和公共衛生舉措，以減輕心血管疾病（CVD）的負擔。在北美和歐洲等地區，完善的保險覆蓋範圍和處方藥計劃使患者能夠獲得他汀類藥物和先進的降血脂療法。各國政府和監管機構，例如美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA），正在持續核准成本效益的學名藥，並鼓勵進行心血管疾病預防方面的研究，這進一步提振了抗高血脂症藥物市場的前景。例如，2024年11月，Esperion宣布大塚製藥株式會社（Otsuka Pharmaceutical Co., Ltd.，簡稱大塚製藥）已向日本厚生勞動省提交了新藥認證高膽固醇症（NDA），擬在日本生產和銷售貝培多酸，用於治療高膽固醇血症和遺傳性高膽固醇症。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球降血脂藥物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 他汀類藥物
  • 膽汁酸吸附劑
  • 膽固醇吸收抑制劑
  • 貝特類衍生物
  • PCSK9抑制劑
  • 同時用藥
  • 其他

第7章 市場區隔：依給藥途徑

  • 口服
  • 靜脈注射

第8章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售店
  • 線上零售商

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112026A5622

The global antihyperlipidemic drugs market size was valued at USD 13.6 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 19.2 Billion by 2034, exhibiting a CAGR of 3.78% during 2026-2034. North America currently dominates the market, holding a significant market share of over 32.7% in 2025. The market in North America is fueled by the high prevalence of hyperlipidemia and cardiovascular diseases, aging populations, obesity, sedentary lifestyles, and unhealthy diets. Strong R&D investments, advanced healthcare infrastructure, government initiatives, rising adoption of statins, PCSK9 inhibitors, and novel lipid-lowering drugs, along with insurance coverage, further fuel antihyperlipidemic drugs market share.

The market is driven by the rising prevalence of hyperlipidemia and cardiovascular diseases, which remain the leading causes of mortality globally. Aging populations, obesity, and sedentary lifestyles contribute to increased cholesterol levels, fueling demand for lipid-lowering medications. The widespread use of statins, fibrates, bile acid sequestrants, and PCSK9 inhibitors, along with emerging therapies like bempedoic acid, is expanding treatment options. Government initiatives promoting cholesterol management, preventive healthcare, and reimbursement policies further support market growth. New approaches in drug delivery combine treatments and individual medical strategies to improve the results of treatments. Advanced healthcare awareness coupled with expanded insurance coverage and sustained research and development investments by pharmaceutical organizations promotes innovative solutions that drive the expansion of both developed and emerging economies markets.

The market for antihyperlipidemic drugs in the United States is driven by the high prevalence of hyperlipidemia, obesity, and cardiovascular diseases, which remain the leading causes of morbidity and mortality. According to the American Journal of Preventive Medicine (AJPM), hyperlipidemia is frequent among the American population. In the United States, approximately 32.8% of adult men and 36.2% of adult females had total cholesterol levels of >=200 mg/dL and low-density lipoprotein cholesterol levels of >=130 mg/dL. Aging populations, sedentary lifestyles, and poor dietary habits contribute to rising cholesterol levels, increasing the demand for lipid-lowering medications. The widespread adoption of statins, PCSK9 inhibitors, and novel lipid-lowering therapies is supported by strong healthcare infrastructure, insurance coverage, and government initiatives promoting cardiovascular health. The FDA's approval of new lipid-lowering drugs, continuous pharmaceutical R&D investments, and the expansion of personalized medicine and biologic therapies further accelerate market growth in the country.

ANTIHYPERLIPIDEMIC DRUGS MARKET TRENDS:

Rising Prevalence of Hyperlipidemia and Cardiovascular Diseases

The growing incidence of hyperlipidemia, obesity, and cardiovascular diseases (CVDs) is a primary driver of the antihyperlipidemic drugs market. For instance, in 2024, more than one billion people worldwide are estimated to be obese, including around 880 million adults and 159 million children and adolescents between the ages of 5 and 19, according to data released by the NCD Risk Factor Collaboration (NCD-RisC). According to data analyzed by the World Obesity Federation, around 3 billion people are overweight or obese and the majority of people on the planet reside in countries where being overweight or obese poses a greater health risk than being underweight. Unhealthy dietary habits, sedentary lifestyles, and genetic predisposition contribute to high cholesterol levels, increasing the demand for lipid-lowering drugs. Heart attacks, strokes, and atherosclerosis are leading causes of mortality worldwide, pushing healthcare providers to prescribe statins, PCSK9 inhibitors, and other lipid-lowering therapies. Governments and healthcare organizations are promoting cholesterol management programs, further fueling market growth. As CVDs remain a major public health concern, the demand for effective long-term cholesterol control solutions continues to rise.

Advancements in Lipid-Lowering Therapies and Drug Innovations

Continuous research and development (R&D) in antihyperlipidemic drugs has led to the development of novel drug classes such as PCSK9 inhibitors (evolocumab, alirocumab), bempedoic acid, and combination therapies. While statins dominate the market, newer therapies offer alternative treatment options for patients with statin intolerance or high-risk lipid profiles. Gene-based treatments and biologics are gaining traction, improving efficacy and patient compliance. FDA approvals for novel drugs and clinical trials exploring next-generation lipid-lowering agents are further driving competition. Pharmaceutical companies are investing in precision medicine, AI-driven drug discovery, and combination drug formulations to enhance cholesterol management solutions. For instance, in February 2025, the FDA authorized Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved medication for CTX, a rare lipid storage syndrome.

Government Initiatives and Expanding Healthcare Coverage

Government-led preventive healthcare programs and awareness campaigns are driving demand for lipid-lowering medications. Many countries have established cholesterol screening guidelines, reimbursement policies, and public health initiatives to reduce the burden of CVDs. In regions like North America and Europe, strong insurance coverage and prescription drug plans ensure patient access to statins and advanced lipid-lowering therapies. Governments and regulatory bodies such as the FDA and EMA continue to approve cost-effective generics and encourage research in cardiovascular disease prevention, further creating a positive antihyperlipidemic drugs market outlook. For instance, in November 2024, Esperion stated that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has filed a New Drug Application (NDA) with the Japanese Ministry of Health, Labour, and Welfare to manufacture and sell bempedoic acid in Japan for the treatment of hypercholesterolemia and familial hypercholesterolemia.

ANTIHYPERLIPIDEMIC DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Statins stand as the largest drug class in 2025, holding around 38.7% of the market due to their proven efficacy in lowering LDL cholesterol, reducing cardiovascular risks, and preventing heart attacks and strokes. They are the first-line therapy for hyperlipidemia and widely prescribed due to their cost-effectiveness, availability, and strong clinical backing. Statins like atorvastatin, rosuvastatin, and simvastatin dominate the market due to their long-term safety profile, widespread adoption, and inclusion in treatment guidelines. Additionally, expanding insurance coverage, generic drug availability, and increasing awareness of cholesterol management contribute to their dominance. Their role in primary and secondary prevention of cardiovascular diseases further solidifies their market leadership.

Analysis by Route of Administration:

  • Oral
  • Intravenous

Oral formulations hold a major share in the market due to their ease of administration, high patient compliance, and widespread availability. Statins, the most prescribed lipid-lowering drugs, are mostly taken orally, making them the dominant treatment option. Other oral drugs like ezetimibe, fibrates, and bile acid sequestrants further contribute to market share. The affordability of oral medications, combined with long-term cholesterol management needs and generic drug availability, strengthens their market presence in both developed and emerging economies.

Intravenous (IV) formulations are expected to hold a significant share due to the rising demand for PCSK9 inhibitors and advanced lipid-lowering therapies. Patients with severe hypercholesterolemia or statin intolerance often receive IV-administered monoclonal antibodies like evolocumab and alirocumab, which offer rapid and effective cholesterol reduction. Hospitals and specialty clinics prefer IV therapies for high-risk patients requiring immediate lipid control. Increased adoption of targeted biologics, ongoing clinical trials, and physician preference for hospital-administered treatments further drive the IV segment's market growth.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Hospital pharmacies hold the major share in the antihyperlipidemic drugs market due to the high volume of prescriptions for cardiovascular disease management in hospitals. Patients with acute coronary syndromes , strokes, and other cardiovascular conditions often receive statins and other lipid-lowering therapies as part of hospital treatment and post-discharge care. Hospitals ensure consistent drug availability, immediate access to critical medications, and adherence to treatment protocols. Additionally, physician-directed prescriptions, better patient monitoring, and integration with insurance and reimbursement systems make hospital pharmacies a preferred distribution channel. The increasing number of cardiovascular procedures, routine lipid screenings, and inpatient care facilities further drive their dominance.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 32.7%. The market in North America is driven by the high prevalence of hyperlipidemia, obesity, and cardiovascular diseases, which are leading causes of mortality. The region has a well-established healthcare infrastructure, advanced lipid-lowering therapies, and strong R&D investments in drug development. Widespread adoption of statins, PCSK9 inhibitors, and novel therapies is supported by government initiatives, insurance coverage, and preventive healthcare programs. The aging population, sedentary lifestyles, and unhealthy dietary habits further fuel demand. Additionally, clinical advancements, FDA approvals for new lipid-lowering drugs, and strategic collaborations between pharmaceutical companies contribute to market expansion in the United States and Canada.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

In 2025, the United States accounted for over 90.00% of the antihyperlipidemic drugs market in North America. The United States is witnessing a growing antihyperlipidemic drugs adoption due to growing investment in pharmaceutical sectors, driving the expansion of drug manufacturing and research. According to reports, in the US pharmaceutical industry, there were 25 private equity deals announced in Q3 2024, worth a total value of USD 2.3 Billion. With pharmaceutical sectors focusing on innovation, the demand for advanced antihyperlipidemic drugs continues to rise. Increasing financial support for pharmaceutical sectors enhances the development of novel therapies, facilitating wider accessibility and improved treatment options. The commitment of pharmaceutical sectors to technological advancements contributes to the efficiency of antihyperlipidemic drugs, ensuring better patient adherence. Expanding pharmaceutical sectors encourage collaborations and clinical trials, further strengthening the market. The focus on research in pharmaceutical sectors leads to the introduction of enhanced formulations, catering to the rising demand. Investments in pharmaceutical sectors support the establishment of specialized healthcare units, ensuring effective drug distribution. The rising competition within pharmaceutical sectors results in cost-effective solutions, increasing affordability. Pharmaceutical sectors' efforts to develop targeted therapies enhance the effectiveness of antihyperlipidemic drugs, promoting their adoption. As pharmaceutical sectors integrate digital tools, accessibility and distribution channels improve, ensuring a wider reach.

ASIA PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Asia-Pacific is experiencing a growing antihyperlipidemic drugs adoption due to growing cholesterol related disease, increasing the demand for effective lipid-lowering treatments. According to survey, 31% of Indians struggle with high cholesterol, with Kerala topping the list with an alarming 63% prevalence. Rising cholesterol related disease prevalence has intensified the focus on preventive healthcare, driving antihyperlipidemic drugs demand. Increased awareness of cholesterol related disease encourages early diagnosis, leading to higher prescription rates. Growing dietary and lifestyle changes contribute to cholesterol related disease, necessitating medical intervention. Healthcare initiatives addressing cholesterol related disease emphasize the need for long-term antihyperlipidemic drugs therapy. The healthcare sector is integrating screening programs to detect cholesterol related disease early, facilitating wider drug adoption. With urbanization influencing dietary habits, cholesterol related disease cases continue to surge, strengthening market growth. The expansion of healthcare networks supports the accessibility of antihyperlipidemic drugs, mitigating cholesterol related disease risks. Medical advancements in cholesterol related disease management improve treatment efficacy, reinforcing antihyperlipidemic drugs' role. As cholesterol related disease becomes a significant concern, governments and private institutions invest in research, fostering pharmaceutical innovation.

EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Europe is experiencing a growing antihyperlipidemic drugs adoption due to growing coronary artery disease (CAD) cases, necessitating effective treatment options. According to reports, in 2021 there were 1.71 Million deaths in the EU resulting from diseases of the circulatory system, which was equivalent to 32.4% of all deaths. The increasing burden of coronary artery disease drives demand for long-term lipid management solutions, boosting antihyperlipidemic drugs usage. Healthcare policies addressing coronary artery disease prioritize early intervention, expanding prescription rates. The growing aging population is more susceptible to coronary artery disease, elevating antihyperlipidemic drugs demand. With healthcare systems implementing preventive measures for coronary artery disease, regular cholesterol monitoring is increasing. Research and development targeting coronary artery disease enhance antihyperlipidemic drugs' effectiveness, strengthening market growth. The rise in sedentary lifestyles and dietary habits contributes to coronary artery disease, emphasizing pharmaceutical intervention. Pharmaceutical advancements in coronary artery disease management introduce improved formulations, ensuring better patient adherence. Healthcare institutions are expanding coronary artery disease awareness programs, promoting antihyperlipidemic drugs usage. Government initiatives tackling coronary artery disease support antihyperlipidemic drugs accessibility, ensuring widespread adoption.

LATIN AMERICA ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Latin America is witnessing growing antihyperlipidemic drugs adoption due to growing online retailers. According to reports, the Latin America market currently boasts over 300 Million digital buyers. Expanding digital healthcare platforms are improving patient access to lipid-lowering medications, driving market penetration. The increasing convenience of online pharmacies is simplifying prescription fulfilment, encouraging higher adoption rates. Competitive pricing and discount offer on digital platforms are enhancing affordability, promoting sustained drug consumption. The rising presence of e-commerce in pharmaceutical distribution is streamlining product availability, ensuring widespread reach. The growing preference for digital healthcare solutions is strengthening consumer reliance on online pharmaceutical services, reinforcing antihyperlipidemic drug sales. Strengthening logistics networks are further improving drug delivery efficiency, boosting accessibility.

MIDDLE EAST AND AFRICA ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Middle East and Africa are experiencing growing antihyperlipidemic drugs adoption due to growing healthcare facilities. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. Expanding hospital networks and specialty clinics are improving patient access to lipid-lowering treatments, fuelling market growth. Increasing government investment in healthcare infrastructure is strengthening antihyperlipidemic drug availability, ensuring widespread distribution. The rising number of cardiology centers is driving greater prescription rates, bolstering demand. Growing medical advancements are facilitating early diagnosis and cholesterol management, encouraging sustained drug utilization. Expanding pharmaceutical supply chains are enhancing distribution efficiency, ensuring consistent access to antihyperlipidemic medications.

COMPETITIVE LANDSCAPE:

The market is highly competitive, with key players focusing on drug innovation, strategic partnerships, and regulatory approvals. Leading pharmaceutical companies such as Pfizer, Merck & Co., AstraZeneca, Novartis, Amgen, and Sanofi dominate the market through extensive R&D and strong global distribution networks. Statins remain the largest drug class, with atorvastatin and rosuvastatin widely prescribed. The emergence of PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent) has intensified competition, offering alternatives for statin-intolerant patients. Patent expirations of branded statins have led to an influx of generic competition, lowering costs. Companies are also investing in novel lipid-lowering drugs, combination therapies, and biologics to maintain market leadership amid evolving healthcare regulations and reimbursement policies.

The report provides a comprehensive analysis of the competitive landscape in the antihyperlipidemic drugs market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • AstraZeneca plc
  • Daiichi Sankyo Company Limited
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the antihyperlipidemic drugs market?

2. What is the future outlook of the antihyperlipidemic drugs market?

3. What are the key factors driving the antihyperlipidemic drugs market?

4. Which region accounts for the largest antihyperlipidemic drugs market share?

5. Which are the leading companies in the global antihyperlipidemic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players